A global biopharmaceutical company headquartered in London announced the layoffs of 150 Massachusetts employees last week.

Amid plans to transfer manufacturing for an investigational vaccine to a souped-up plant in Pennsylvania, GSK is parting ways ...

The Cambridge site of an international biotechnology company will cease manufacturing, leaving 150 people without a job.

British biopharmaceutical company GlaxoSmithKline will lay off 150 employees in its Cambridge operations by the end of March 2026, the company said in a notice to the state. The company said Monday ...

We recently published a list of Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other ...

The funding, which brings GSK’s expenditure in US manufacturing capabilities close to $1.3bn, will establish a new vaccines drug substance facility and an R&D pilot plant.

After making a splash in the U.K. earlier this year, GSK is laying out plans for its biggest U.S. manufacturing investment yet. GSK is investing up to $800 million to double the size and capacity ...

GSK plans to invest $800 million in its East Donegal Township vaccine packaging facility over the next four years in an expansion project that would add research and manufacturing capabilities.

We recently published a list of Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now.In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other ...